Skip to content
Prostate Cancer Research Center

Faculty of Medicine and Health Technology

Computational Biology

2020

Search PubMed

2019

Search PubMed

2018

Search PubMed

2017

Search PubMed

2016

  1. Grönroos, T, Teppo, S, Mehtonen, J, Laukkanen, S, Liuksiala, T, Nykter, M et al.. Overexpression of PTP4A3 in ETV6-RUNX1 acute lymphoblastic leukemia. Leuk Res. 2017;54 :1-6. doi: 10.1016/j.leukres.2016.12.005. PubMed PMID:28063378 .
  2. Ulman, V, Svoboda, D, Nykter, M, Kozubek, M, Ruusuvuori, P. Virtual cell imaging: A review on simulation methods employed in image cytometry. Cytometry A. 2016;89 (12):1057-1072. doi: 10.1002/cyto.a.23031. PubMed PMID:27922735 .
  3. Teppo, S, Laukkanen, S, Liuksiala, T, Nordlund, J, Oittinen, M, Teittinen, K et al.. Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia. Genome Res. 2016;26 (11):1468-1477. doi: 10.1101/gr.193649.115. PubMed PMID:27620872 PubMed Central PMC5088590.
  4. Määttä, K, Rantapero, T, Lindström, A, Nykter, M, Kankuri-Tammilehto, M, Laasanen, SL et al.. Whole-exome sequencing of Finnish hereditary breast cancer families. Eur J Hum Genet. 2016;25 (1):85-93. doi: 10.1038/ejhg.2016.141. PubMed PMID:27782108 PubMed Central PMC5159774.
  5. Cordova, ZM, Grönholm, A, Kytölä, V, Taverniti, V, Hämäläinen, S, Aittomäki, S et al.. Myeloid cell expressed proprotein convertase FURIN attenuates inflammation. Oncotarget. 2016;7 (34):54392-54404. doi: 10.18632/oncotarget.11106. PubMed PMID:27527873 PubMed Central PMC5342350.
  6. Wyatt, AW, Azad, AA, Volik, SV, Annala, M, Beja, K, McConeghy, B et al.. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016;2 (12):1598-1606. doi: 10.1001/jamaoncol.2016.0494. PubMed PMID:27148695 PubMed Central PMC5097690.
  7. Bova, GS, Kallio, HM, Annala, M, Kivinummi, K, Högnäs, G, Häyrynen, S et al.. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Cold Spring Harb Mol Case Stud. 2016;2 (3):a000752. doi: 10.1101/mcs.a000752. PubMed PMID:27148588 PubMed Central PMC4853517.
  8. Nurminen, R, Rantapero, T, Wong, SC, Fischer, D, Lehtonen, R, Tammela, TL et al.. Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. Genes Chromosomes Cancer. 2016;55 (8):661-73. doi: 10.1002/gcc.22368. PubMed PMID:27113481 .
  9. Ruusuvuori, P, Valkonen, M, Nykter, M, Visakorpi, T, Latonen, L. Feature-based analysis of mouse prostatic intraepithelial neoplasia in histological tissue sections. J Pathol Inform. 2016;7 :5. doi: 10.4103/2153-3539.175378. PubMed PMID:26955503 PubMed Central PMC4763506.
  10. Sjöblom, L, Saramäki, O, Annala, M, Leinonen, K, Nättinen, J, Tolonen, T et al.. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. PLoS One. 2016;11 (3):e0150241. doi: 10.1371/journal.pone.0150241. PubMed PMID:26939004 PubMed Central PMC4777373.
  11. Alarmo, EL, Havunen, R, Häyrynen, S, Penkki, S, Ketolainen, J, Nykter, M et al.. Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion. Genes Chromosomes Cancer. 2016;55 (3):227-36. doi: 10.1002/gcc.22324. PubMed PMID:26684238 .

Search PubMed

2015

  1. Alarmo, EL, Havunen, R, Häyrynen, S, Penkki, S, Ketolainen, J, Nykter, M et al.. Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion. Genes Chromosomes Cancer. 2016;55 (3):227-36. doi: 10.1002/gcc.22324. PubMed PMID:26684238 .
  2. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163 (4):1011-25. doi: 10.1016/j.cell.2015.10.025. PubMed PMID:26544944 PubMed Central PMC4695400.
  3. Ylipää, A, Kivinummi, K, Kohvakka, A, Annala, M, Latonen, L, Scaravilli, M et al.. Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. Cancer Res. 2015;75 (19):4026-31. doi: 10.1158/0008-5472.CAN-15-0217. PubMed PMID:26282172 .
  4. Rane, JK, Ylipää, A, Adamson, R, Mann, VM, Simms, MS, Collins, AT et al.. Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data. Br J Cancer. 2015;113 (4):611-5. doi: 10.1038/bjc.2015.262. PubMed PMID:26203762 PubMed Central PMC4647689.
  5. Nordfors, K, Haapasalo, J, Mäkelä, K, Granberg, KJ, Nykter, M, Korja, M et al.. Twist predicts poor outcome of patients with astrocytic glioma. J Clin Pathol. 2015;68 (11):905-12. doi: 10.1136/jclinpath-2015-202868. PubMed PMID:26163539 .
  6. Kaukoniemi, KM, Rauhala, HE, Scaravilli, M, Latonen, L, Annala, M, Vessella, RL et al.. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med. 2015;4 (9):1417-25. doi: 10.1002/cam4.486. PubMed PMID:26129688 PubMed Central PMC4567026.
  7. Marttila, S, Kananen, L, Häyrynen, S, Jylhävä, J, Nevalainen, T, Hervonen, A et al.. Ageing-associated changes in the human DNA methylome: genomic locations and effects on gene expression. BMC Genomics. 2015;16 (1):179. doi: 10.1186/s12864-015-1381-z. PubMed PMID:25888029 PubMed Central PMC4404609.
  8. Gundem, G, Van Loo, P, Kremeyer, B, Alexandrov, LB, Tubio, JMC, Papaemmanuil, E et al.. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520 (7547):353-357. doi: 10.1038/nature14347. PubMed PMID:25830880 PubMed Central PMC4413032.
  9. Annala, M, Kivinummi, K, Tuominen, J, Karakurt, S, Granberg, K, Latonen, L et al.. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. Oncotarget. 2015;6 (8):6235-50. doi: 10.18632/oncotarget.3359. PubMed PMID:25749039 PubMed Central PMC4467434.
  10. Turner, KM, Sun, Y, Ji, P, Granberg, KJ, Bernard, B, Hu, L et al.. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A. 2015;112 (11):3421-6. doi: 10.1073/pnas.1414573112. PubMed PMID:25737557 PubMed Central PMC4371922.
  11. Scaravilli, M, Porkka, KP, Brofeldt, A, Annala, M, Tammela, TL, Jenster, GW et al.. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. Prostate. 2015;75 (8):798-805. doi: 10.1002/pros.22961. PubMed PMID:25731699 .
  12. Veskimäe, K, Staff, S, Tabaro, F, Nykter, M, Isola, J, Mäenpää, J et al.. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies. Genes Chromosomes Cancer. 2015;54 (5):276-87. doi: 10.1002/gcc.22241. PubMed PMID:25706666 .
  13. Rane, JK, Scaravilli, M, Ylipää, A, Pellacani, D, Mann, VM, Simms, MS et al.. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur Urol. 2015;67 (1):7-10. doi: 10.1016/j.eururo.2014.09.005. PubMed PMID:25234358 .
  14. Li, X, Liu, Y, Granberg, KJ, Wang, Q, Moore, LM, Ji, P et al.. Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene. 2015;34 (13):1619-1628. doi: 10.1038/onc.2014.98. PubMed PMID:24747968 PubMed Central PMC4205227.

Search PubMed